1. Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma. (September 2022) Authors: Kawakita, Daisuke; Nagao, Toshitaka; Takahashi, Hideaki; Kano, Satoshi; Honma, Yoshitaka; Hirai, Hideaki; Saigusa, Natsuki; Akazawa, Kohei; Tani, Kaori; Ojiri, Hiroya; Tsukahara, Kiyoaki; Ozawa, Hiroyuki; Okami, Kenji; Kondo, Takahito; Togashi, Takafumi; Fushimi, Chihiro; Shimura, Tomotaka; Shimi... Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗